ArticleDigestive diseases and sciences2016
Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA.
Article in Digestive diseases and sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The prevalence of clarithromycin-resistantPeerJ · 2023Pooled it
- Real-world evidence of a novel tetravalent immunoglobulin Y effectiveness and safety in patients with the refractory Helicobacter pylori infection.BMC infectious diseases · 2024Trial
- Whole genome sequence analysis ofiScience · 2025Article
- Article
- RETRACTED: The Impact ofInternational journal of molecular sciences · 2025Review
- First-Line Prescriptions and Effectiveness ofAntibiotics (Basel, Switzerland) · 2025Article
- Newer Therapies for RefractoryAntibiotics (Basel, Switzerland) · 2024Review
- Molecular tools of antibiotic resistance forFrontiers in gastroenterology (Lausanne, Switzerland) · 2024Review
- Unpacking the Racial Gap: Helicobacter pylori Infection Clearance Among Different Racial Groups.Cureus · 2023Article
- Pyrosequencing analysis for rapid and accurate detection of clarithromycin resistance-associated mutations in Iranian Helicobacter pylori isolates.BMC research notes · 2023Article
- Novel Mutations Conferring Amoxicillin Resistance inAntibiotics (Basel, Switzerland) · 2023Article
- The Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy forAntibiotics (Basel, Switzerland) · 2023Review
- Sex and age differences in mortality trends of gastric cancer among Hispanic/Latino populations in the United States, Latin America, and the Caribbean.Lancet regional health. Americas · 2022Article
- Pitfalls of Physician-Directed Treatment of Helicobacter pylori: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data.Digestive diseases and sciences · 2022Review
- Linolenic Acid-Metronidazole: a Compound Relieving Drug Resistance and Inhibiting Helicobacter pylori.Antimicrobial agents and chemotherapy · 2022Article
- Genotypic detection of metronidazole and clarithromycin resistance in dyspeptic patients with helicobacter pylori.Environmental science and pollution research international · 2022Article
- Multicenter Evaluation of a Gradient Diffusion Method for Antimicrobial Susceptibility Testing of Helicobacter pylori.Microbiology spectrum · 2022Article
- Increased Antibiotic Resistance in Children withPathogens (Basel, Switzerland) · 2022Article
- Two New Fatty Acid Derivatives, Omphalotols A and B and Anti-Pharmaceuticals (Basel, Switzerland) · 2022Article
- Racial Differences inGastro hep advances · 2022Article
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHelicobacter pylori antibiotic resistance leads to frequent treatment failure. However, the current US prevalence of H. pylori clarithromycin resistance and treatment failure is unknown.
aimsTo determine the prevalence of clarithromycin-resistant H. pylori and its impact on treatment failure in the USA.
methodsA multicenter, retrospective, cohort study for clarithromycin-resistant H. pylori was conducted over four academic medical centers in different geographic regions of the USA. Gastric biopsy material, residual from standard clinical pathologic examination, was examined for clarithromycin resistance by DNA sequencing of H. pylori 23S rRNA.
resultsOne hundred and twenty-four cases of H. pylori gastritis were examined from medical centers in four different geographic regions of the USA. The overall prevalence of clarithromycin resistance was 32.3 % (range 23.1-45.8 %). There was no significant difference in the prevalence of clarithromycin resistance by study site, gender, age, or race/ethnicity. In a subset of 67 patients that had clinical follow-up data, the overall prevalence of clarithromycin resistance was 31.3 %. There was a 2.9-fold increase (p = 0.002) in treatment failure for cases with clarithromycin resistance (57.1 %) compared to wildtype H. pylori (19.6 %).
conclusionsH. pylori clarithromycin resistance in the USA exceeds the estimated 20 % prevalence compatible with successful empiric antibiotic therapy. This resistance resulted in a significant rate of treatment failure in all sites surveyed. Empiric therapy in the USA should be used with caution until there is better regional or local determination of H. pylori antibiotic resistance.
Indexed as
Identifiers
26923948What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.